Skip to content
Telehealth Graded
Peptide evidence

BPC-157: what the FDA actually said, and what the trials show

Search PubMed for a clinical trial of BPC-157 and you get nothing. Not a small trial, not a failed one — zero, against 344 for semaglutide through the same filter on the same day. The FDA, meanwhile, has looked at BPC-157 twice and both times ended up in the same place: it doesn't have enough safety information to say whether the peptide would hurt someone.

Evidence read September 2026. Nobody here holds a medical license and none of this is medical advice. Every source below is listed so you can check it yourself.

What this comes down to

  • No completed clinical trial of BPC-157 appears in PubMed. The peptide has 228 indexed records, almost all of them animal work.
  • The FDA placed BPC-157 in category 2 of its compounding interim policy — the category for substances with identified significant safety risks — and the nomination was later withdrawn by whoever filed it.
  • BPC-157 is not the active ingredient of any product in Drugs@FDA, and it is not on the 503A bulks list, so a pharmacy compounding it is outside the three routes the FDA names.
  • The one published paper describing human patients is a chart review of 17 people at a single clinic, not a trial.
Clinical trials in PubMed
0
Same filter returns 344 for semaglutide
Total PubMed records
228
Mostly animal studies
FDA compounding category
Category 2, then withdrawn
Approved products containing it
None

The trial record is empty, and that is a finding

BPC-157 has been studied since the 1990s, so the absence isn't for lack of time. It's that essentially all of the work is preclinical — rats, tendon explants, cell culture. Run the search with a trial filter attached and it returns nothing at all, while the same filter applied to semaglutide returns 344 papers and to tesamorelin, a much smaller peptide drug, returns 28. The filter works. There is just nothing on the other side of it.

The search behind that claim

PubMed, via the E-utilities API

("BPC 157") AND ("clinical trial"[pt] OR "randomized controlled trial"[pt])

Returned 0. Positive control — semaglutide, identical filter — returned 344 through the identical filter in the same session. Read September 2026.

A second control, tesamorelin, returned 28 through the same filter. Unfiltered, “BPC 157” returns 228 records and 53 carry PubMed's human indexing tag — that tag marks papers about humans, not trials in humans.

One paper does describe real patients. It's a retrospective chart review at a single hormone clinic in Orlando, covering 17 people who got BPC-157 injected into a knee, published in a complementary-medicine journal[1]. Sixteen were reached by phone afterward and asked to rate their pain from memory. That's a case series with a follow-up call attached — useful for deciding whether something is worth studying, not for deciding whether it works.

What the FDA has on the record

A pharmacy compounding under section 503A can only use a bulk substance that meets one of three conditions: it complies with a USP or National Formulary monograph, or it's a component of an FDA-approved drug product, or it appears on the FDA's 503A bulks list[2]. BPC-157 isn't on the bulks list. It also isn't the active ingredient of anything in Drugs@FDA — we queried the database by ingredient, and a deliberately fake ingredient name returned the same empty result, so we ran tesamorelin through as a control and it came back with one approved product[4].

It went further than that. When the agency sorted the substances people had nominated for the bulks list, BPC-157 landed in category 2 — the bucket for substances where the FDA has identified significant safety risks and says plainly it does not intend to extend its hands-off policy. The nomination was later withdrawn by the party that filed it, which is why BPC-157 now sits in the withdrawn table rather than the live one[3]. Withdrawal isn't exoneration. The safety text the agency wrote is still published beside the name.

“Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.”

[3]
Read that carefully — it isn't a safety finding

The FDA didn't say BPC-157 is dangerous. It said it doesn't know, and that not knowing is itself the problem for an injectable a compounder would make in batches. Two separate concerns are stacked in there: whether the molecule does harm, and whether a given vial contains what the label says. Peptide impurities and characterization are the second question, and a page that only argues about the first one is answering half of it.

What that means for a company selling it to you

A telehealth company offering BPC-157 is offering a compounded preparation of a substance with no approved product behind it and no trial record to point at. Some are upfront about that. Others describe it in the register normally reserved for medicine, which is where the FDA's authority over promotional claims comes in: prescription drug promotion by a compounder has to be truthful and non-misleading, and the agency says it monitors it[5].

Our own read of a seller is about the seller — what it publishes, what it withholds, and what it charges once the introductory rate ends. The method is on how we grade, and the price rules are on how we verify prices. Neither is a judgment about whether a molecule works, and this article isn't one either.

Where BPC-157 sits against the rest of the peptide menu

It is not the weakest thing on a typical peptide menu, and it is nowhere near the strongest. We put every peptide these companies sell through the same two questions — is there an approved product, and how many randomized trials exist — in the peptide status table.

Questions people actually ask

Is BPC-157 legal to buy in the United States?

It isn't a scheduled drug, but it also isn't an approved one, and it isn't on the FDA's 503A bulks list — so a pharmacy compounding it is operating outside the three routes the agency names for bulk substances. Products sold as research chemicals and labeled not for human consumption are a separate problem: the FDA has warned companies for selling exactly that kind of listing directly to consumers with dosing instructions attached.

Has BPC-157 been tested in humans at all?

Not in a completed clinical trial that PubMed indexes. One published paper describes 17 patients at a single clinic who had it injected into a knee, reviewed retrospectively from their charts. Everything else in the literature is animal or laboratory work.

Why do so many telehealth companies sell it then?

Because compounding sits outside the approval process, and demand for it is real. A compounded preparation doesn't need a trial behind it to be dispensed on a prescription, which is the same mechanism that lets compounded GLP-1s exist. The difference is that semaglutide has hundreds of trials and an approved product; BPC-157 has neither.

Does the FDA say BPC-157 is unsafe?

No. It says it lacks enough safety information to know whether the peptide would cause harm in people, and that compounded versions carry risks around immunogenicity and impurities. Those are different statements, and the difference matters.

Sources

Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it.

  1. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine, 2021. PMID 34324435 · Read September 2026
    The only published paper describing human patients given BPC-157 is a retrospective chart review of 17 patients at one clinic, with 16 reached by telephone for follow-up.
  2. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. U.S. Food and Drug Administration, 2026. Source · Read September 2026
    A 503A compounder may use a bulk substance only if it meets a USP or NF monograph, is a component of an FDA-approved drug product, or appears on the 503A bulks list.
  3. Substances in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration, 2026. Source · Document dated April 2026; read September 2026
    BPC-157 was placed in category 2 of the FDA's compounding interim policy and appears in the table of nominations later withdrawn by the nominators, with the agency's safety text published beside it.
  4. Drugs@FDA: FDA-Approved Drugs, queried through the openFDA API. U.S. Food and Drug Administration, 2026. Source · Read September 2026
    No approved product in Drugs@FDA lists BPC-157 as an active ingredient; a control query for tesamorelin returned one approved product through the identical method.
  5. Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, 2025. Source · Document dated September 2025; read September 2026
    Prescription drug promotion by or on behalf of compounders must be truthful, non-misleading and accurate, and the FDA says it monitors promotional material.